X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19489) 19489
Book Review (2973) 2973
Publication (1538) 1538
Book Chapter (66) 66
Conference Proceeding (46) 46
Magazine Article (36) 36
Dissertation (25) 25
Newsletter (10) 10
Book / eBook (8) 8
Web Resource (7) 7
Newspaper Article (6) 6
Reference (6) 6
Paper (5) 5
Government Document (2) 2
Trade Publication Article (2) 2
Data Set (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15740) 15740
humans (13147) 13147
imatinib mesylate (11769) 11769
benzamides (6845) 6845
male (6004) 6004
female (5301) 5301
oncology (5193) 5193
pyrimidines - therapeutic use (4956) 4956
piperazines - therapeutic use (4749) 4749
antineoplastic agents - therapeutic use (4305) 4305
middle aged (4212) 4212
animals (3821) 3821
adult (3712) 3712
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3561) 3561
aged (3179) 3179
imatinib (3147) 3147
hematology (3062) 3062
chronic myelogenous leukemia (2710) 2710
pyrimidines - pharmacology (2515) 2515
chronic myeloid-leukemia (2511) 2511
piperazines - pharmacology (2365) 2365
treatment outcome (2344) 2344
cancer (2083) 2083
protein kinase inhibitors - therapeutic use (1955) 1955
chronic myeloid leukemia (1892) 1892
mutation (1702) 1702
antineoplastic agents - pharmacology (1691) 1691
pharmacology & pharmacy (1591) 1591
mice (1552) 1552
protein-tyrosine kinases - antagonists & inhibitors (1542) 1542
mesylate (1522) 1522
leukemia, myelogenous, chronic, bcr-abl positive - genetics (1515) 1515
pyrimidines - administration & dosage (1460) 1460
bcr-abl (1445) 1445
therapy (1413) 1413
leukemia (1390) 1390
gastrointestinal stromal tumors - drug therapy (1374) 1374
piperazines - administration & dosage (1373) 1373
abridged index medicus (1343) 1343
tyrosine kinase (1269) 1269
research (1264) 1264
pyrimidines - adverse effects (1248) 1248
prognosis (1230) 1230
gastrointestinal stromal tumors (1197) 1197
drug resistance, neoplasm (1193) 1193
care and treatment (1179) 1179
tyrosine kinase inhibitor (1177) 1177
leukemia, myelogenous, chronic, bcr-abl positive - pathology (1176) 1176
protein kinase inhibitors - pharmacology (1143) 1143
analysis (1140) 1140
piperazines - adverse effects (1140) 1140
aged, 80 and over (1134) 1134
fusion proteins, bcr-abl - genetics (1133) 1133
adolescent (1131) 1131
cell line, tumor (1120) 1120
antineoplastic agents - adverse effects (1098) 1098
mesylates - pharmacology (1081) 1081
c-kit (1075) 1075
mesylates - chemistry (1052) 1052
biochemistry & molecular biology (1040) 1040
antineoplastic agents (1019) 1019
time factors (1003) 1003
tumors (998) 998
antineoplastic agents - administration & dosage (978) 978
dasatinib (958) 958
rats (949) 949
apoptosis (935) 935
medicine & public health (929) 929
dose-response relationship, drug (926) 926
young adult (910) 910
chemotherapy (901) 901
expression (896) 896
antimitotic agents (894) 894
hemic and lymphatic diseases (889) 889
gastrointestinal stromal tumors - pathology (882) 882
surgery (872) 872
drug therapy (870) 870
apoptosis - drug effects (859) 859
resistance (859) 859
cml (858) 858
proto-oncogene proteins c-kit - genetics (836) 836
cell biology (818) 818
gist (816) 816
tyrosine (803) 803
hematology, oncology and palliative medicine (774) 774
benzamides - therapeutic use (770) 770
retrospective studies (768) 768
in-vitro (764) 764
article (754) 754
gastrointestinal stromal tumor (745) 745
tyrosine kinase inhibitors (714) 714
diagnosis (705) 705
imatinib mesylate - therapeutic use (690) 690
mutations (685) 685
cells (684) 684
follow-up studies (677) 677
mesylates (674) 674
fusion proteins, bcr-abl - metabolism (672) 672
philadelphia-chromosome (670) 670
health aspects (664) 664
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17690) 17690
Japanese (381) 381
German (357) 357
French (354) 354
Chinese (311) 311
Spanish (120) 120
Russian (110) 110
Italian (66) 66
Polish (47) 47
Portuguese (42) 42
Korean (34) 34
Czech (29) 29
Hungarian (27) 27
Danish (12) 12
Croatian (11) 11
Swedish (10) 10
Dutch (9) 9
Turkish (7) 7
Bulgarian (5) 5
Slovak (4) 4
Finnish (3) 3
Hebrew (3) 3
Norwegian (3) 3
Romanian (3) 3
Serbian (3) 3
Ukrainian (3) 3
Lithuanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Tetrahedron, ISSN 0040-4020, 08/2019, Volume 75, Issue 33, pp. 4570 - 4576
Synthesis of the C1–C13 fragment of eribulin mesylate has been accomplished. It features a highly stereoselective construction of a -dihydropyran framework... 
Eribulin mesylate | Fine chemicals
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 3, pp. 298 - 305
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 10/2006, Volume 103, Issue 40, pp. 14907 - 14912
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2015, Volume 52, pp. 173 - 180
Abstract Background The added value of tumoural genomic profiles to conventional clinico-biological factors to predict progression-free survival (PFS) and... 
Hematology, Oncology and Palliative Medicine | GIST | prognostic factors | outcome analysis | imatinib mesylate | mutational status | RESEARCH GEIS | FREE SURVIVAL | PHASE-III | KIT EXON-11 | MESYLATE | PROGNOSTIC-FACTOR | SPANISH GROUP | ONCOLOGY | MUTATIONS | GASTROINTESTINAL STROMAL TUMORS | INTERRUPTION | Predictive Value of Tests | Gastrointestinal Neoplasms - genetics | Exons | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Gastrointestinal Neoplasms - pathology | Time Factors | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Gastrointestinal Stromal Tumors - pathology | Imatinib Mesylate - adverse effects | Imatinib Mesylate - administration & dosage | Female | Proto-Oncogene Proteins c-kit - genetics | Gastrointestinal Stromal Tumors - mortality | France | Gastrointestinal Stromal Tumors - genetics | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Gastrointestinal Stromal Tumors - drug therapy | Biomarkers, Tumor - genetics | Mutation | Antimitotic agents | Care and treatment | Sarcoma | Antineoplastic agents | Patient outcomes | Standards | Index Medicus | Life Sciences | Cancer
Journal Article
Journal Article
Case Report - Imatinib mesylate induces responses in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy, 12/2006
Background: Imatinib mesylate represents a real major paradigm shift in cancer therapy, targeting the specific molecular abnormalities, crucial in the etiology... 
Liver metastases, GIST, imatinib mesylate, intra arterial hepatic chemotherapy
Journal
Cancer, ISSN 0008-543X, 11/2015, Volume 121, Issue 21, pp. 3894 - 3904
The administration of tyrosine kinase inhibitors may be safe in the setting of chronic kidney disease in patients with chronic myeloid leukemia. 
dasatinib | nilotinib | imatinib | glomerular filtration rate changes | tyrosine kinase inhibitor | kidney injury | outcome | chronic myeloid leukemia (CML) | CHRONIC MYELOGENOUS LEUKEMIA | RENAL-FAILURE SECONDARY | CHRONIC-PHASE | TUMOR LYSIS SYNDROME | EXPERIMENTAL GLOMERULONEPHRITIS | TUBULAR REGENERATION | ONCOLOGY | IMATINIB MESYLATE TREATMENT | IN-VIVO | MESANGIAL CELLS | GROWTH-FACTOR | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Protein Kinase Inhibitors - adverse effects | Glomerular Filtration Rate - physiology | Incidence | Dose-Response Relationship, Drug | Renal Insufficiency, Chronic - epidemiology | Young Adult | Creatinine - metabolism | Glomerular Filtration Rate - drug effects | Imatinib Mesylate - therapeutic use | Kidney - metabolism | Imatinib Mesylate - adverse effects | Aged, 80 and over | Adult | Female | Acute Kidney Injury - chemically induced | Retrospective Studies | Kidney - physiopathology | Kidney - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Imatinib Mesylate - pharmacology | Dasatinib - therapeutic use | Treatment Outcome | Pyrimidines - pharmacology | Dasatinib - pharmacology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Pyrimidines - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Acute Kidney Injury - epidemiology | Renal Insufficiency, Chronic - chemically induced | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Dasatinib | Care and treatment | Myelocytic leukemia | Analysis | Dosage and administration | Nonlymphoid leukemia | Diagnosis | Glomerular filtration rate | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 8/2017, Volume 56, Issue 8, pp. 977 - 985
The aims of this study were to determine the effects of the CYP2C8*3 and *4 polymorphisms on imatinib metabolism and plasma imatinib concentrations in chronic... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | TYROSINE KINASE INHIBITORS | IN-VITRO | ABCB1 | GENETIC POLYMORPHISMS | TRANSPORTER POLYMORPHISMS | POPULATION PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | CLINICAL PHARMACOKINETICS | N-DEMETHYLATION | CYP3A4 | P-GLYCOPROTEIN | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imatinib Mesylate - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Imatinib Mesylate - pharmacokinetics | Imatinib Mesylate - administration & dosage | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Cytochrome P-450 CYP2C8 - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Pharmacogenetics - methods | Cytochrome P-450 CYP2C8 - drug effects | Genotype | Protein Kinase Inhibitors - blood | Polymorphism, Genetic | Protein Kinase Inhibitors - administration & dosage | Imatinib Mesylate - blood | Receptor Protein-Tyrosine Kinases - genetics | Aged | Cytochrome P-450 CYP2C8 - genetics | Clinical Trials, Phase II as Topic | Protein Kinase Inhibitors - metabolism | Care and treatment | Cancer patients | Chronic myeloid leukemia | Research | Cytochrome | Studies | Plasma | Genotype & phenotype | Enzymes | Ratios | Metabolites | Leukemia | Metabolism | Patients | Drug dosages | Index Medicus
Journal Article
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 03/2016, Volume 26, Issue 5, pp. 1419 - 1427
Journal Article
12/2010
Drug-induced pancreatitis is a rare but serious complication of many drugs, some of which have been well documented. Here we present a case of a middle-aged... 
Acute pancreatitis | chronic myeloid leukemia | imatinib mesylate
Web Resource
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 10, pp. 917 - 927
Journal Article